The addition of pevonedistat to azacitidine plus venetoclax failed to significantly improve response rates.

Individuals with tattoos, particularly larger ones, may have an increased risk of lymphoma and skin cancer, according to a recent.

A Viewpoints article published in The Lancet Haematology, calls for further research into the use of measurable residual disease (MRD).

The Brazilian Health Regulatory Agency (ANVISA) has approved ropeginterferon alfa-2b (BESREMi) for the treatment of adult patients with polycythemia vera.

Lisocabtagene maraleucel (liso-cel) was found to offer a favorable benefit–risk profile relative to mosunetuzumab as a third-line or later treatment for.

SOHO is launching a special fundraising initiative now through its Thirteenth Annual Meeting in Houston, Texas, taking place between September.

The European Commission (EC) has granted approval to lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for.

The Center for Drug Evaluation of the China National Medical Products Administration (NMPA) approved the IND application for KPG-818.

A phase 1 study found that “naturally selected” CD7 chimeric antigen receptor T-cell (NS7CAR-T) therapy was well-tolerated and induced complete.

Have a burning question about a patient with B-cell malignancies for Hodgkin or non-Hodgkin lymphoma? Ask Kami Maddocks, MD, professor.

Researchers found that prior use of bendamustine within six months of apheresis was the only baseline variable associated with a.

The European Commission (EC) has approved the marketing authorization for imetelstat (RYTELO), a first-in-class telomerase inhibitor, as a monotherapy for.